Diabetes and Kidney Complications Garnering Attention at ISN Diabetes and Kidney Complications Garnering Attention at ISN

First results indicating that an SGLT2 inhibitor could improve outcomes for patients with diabetes and chronic kidney disease will be presented at the upcoming nephrology world congress.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Nephrology News Source Type: news

Related Links:

Conclusion MethodologyThere were 4 clinical trials approved at the National University Malaysia in collaboration with Cytopeutics (Cyberjaya, Malaysia) which provided the mesenchymal stromal cells (Cyto-MSC) for treatment of acute stroke, heart failure, diabetes with critical limb ischemia and severe deforming osteoarthritis. All patients received 65-130 × 106 Cyto-MSC intravenously. Severity of chronic kidney disease is based on baseline estimated glomerular filtration rate (eGFR) and serum creatinine which are markers of renal dysfunction. These and other blood tests including fasting blood sugar (FBS) and Hba1...
Source: Cytotherapy - Category: Cytology Source Type: research
Authors: Garla VV, Kanduri S, Yanes-Cardozo L, Lien LF Abstract Diabetes mellitus (DM) and Chronic Kidney Disease (CKD) are two chronic diseases whose prevalence and co-prevalence are on the rise. CKD is also the most debilitating and expensive complication of DM while management of DM in CKD is most challenging. CKD is developing in much younger patients with DM, and its presentation is also changing. Various methods of glycemic assessment are affected by CKD and dosage of DM medications needs to be adjusted according to the kidney function. One of the significant barriers to glycemic control in DM patients with C...
Source: Minerva Endocrinologica - Category: Endocrinology Tags: Minerva Endocrinol Source Type: research
AbstractStrongyloides stercoralis (S. stercoralis), a human intestinal nematode, can lead to hyper/disseminated (HD) infection in patients treated with corticosteroids. Here, we report a case of strongyloidiasis in a 58-year-old female with a history of rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM). The patient presented with abdominal pain and gastrointestinal (GI) bleeding. Stool was negative for parasitic agents in the first direct smear examination, and the patient with the probable diagnosis ofHelicobacter pylori (H. pylori) infection or Crohn ’s disease received antibiotics and corticosteroids. ...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
AbstractPurpose of ReviewThe purpose of this review is to emphasize the pivotal role of glucagon-like peptide 1 (GLP-1) in tackling the parallel epidemics of obesity and type 2 diabetes (T2DM).Recent FindingsGLP-1-based therapies and in particular GLP-1 receptor agonists (GLP-1 RA) have proven to be effective in lowering blood glucose and decreasing weight. GLP-1 RA not only mitigate these significant medical burdens but also result in weight loss and weight loss independent factors that decrease cardiovascular disease (CVD) and microvascular complications of T2DM, such as diabetic nephropathy.SummaryGLP-1-based therapies ...
Source: Current Obesity Reports - Category: Eating Disorders & Weight Management Source Type: research
AbstractBackgroundStable ischemic heart disease (SIHD) is prevalent in patients with chronic kidney disease (CKD); however, whether guideline-directed medical therapy (GDMT) is adequately implemented in patients with SIHD and CKD is unknown.HypothesisUse of GDMT and achievement of treatment targets would be higher in SIHD patients without CKD than in patients with CKD.MethodsThis was a retrospective study of 563 consecutive patients with SIHD (mean age 67.8  years, 84% Caucasians, 40% females). CKD was defined as an estimated glomerular filtration rate (eGFR) of
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
Redemption of Medtronic’s renal denervation program to treat hypertension is seemingly on the horizon. The Dublin-based company reported results from an investigator-led study and a registry that demonstrate long-term results of RDN’s impact on uncontrolled hypertension. These results were presented during a Late-Breaking Clinical Trial session at EuroPCR in Paris. In the investigator -led study data indicated RDN with the Medtronic Symplicity system was associated with reduced occurrence of subclinical Atrial Fibrillation (AFib) in a small subset of high-risk patients with hypertensive ...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Business Source Type: news
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
AbstractThe reliability of fractional flow reserve (FFR) in aortic stenosis (AS) has been questioned because of the uncertain response to vasodilators. A retrospective multicenter cohort of 114 AS patients who underwent coronary physiology assessment was compared with 154 controls before and after propensity matching adjustment. The difference between resting distal coronary vs aortic pressure ratio (Pd/Pa) and FFR ( ΔPd/Pa-FFR) was tested against the severity of AS. ΔPd/Pa-FFR was not influenced by the severity of AS in terms of aortic valve area (r = − 0.02,p = 0.83) a...
Source: Journal of Cardiovascular Translational Research - Category: Cardiology Source Type: research
The Dietary Approaches to Stop Hypertension (DASH) diet lowers blood pressure and cardiovascular disease risk. In this issue, Banerjee et  al. report that the DASH diet is associated with lower risk of end-stage kidney disease in individuals with stage 3 chronic kidney disease and hypertension. This association was particulary strong among those with diabetes. The DASH diet may have an important role in preventing end-stage kidney di sease in select individuals with chronic kidney disease.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Commentary Source Type: research
Conclusions: Bariatric surgery increased miR 192 and miR 200 urinary levels, key anti-fibrotic microRNAs that could contribute to a renal-protective mechanism and may be of value as urinary biomarkers following surgery. These findings suggest that urinary microRNAs may represent potential novel biomarkers for obesity-associated renal function.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
More News: Chronic Kidney Disease | Diabetes | Endocrinology | Health | Politics | SGLT2 Inhibitors | Urology & Nephrology